aTyr Pharma (LIFE) Files $86.25M Common Stock IPO

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. aTyr Pharma has applied to list its common stock on The NASDAQ Global Market under the symbol "LIFE".

*** The proposed maximum offering amount is $86.25 million.

J.P. Morgan Securities LLC and Citigroup Global Markets, Inc. will act as lead book-running managers for the proposed offering, BMO Capital Markets Corp. will act as a lead manager for the proposed offering and William Blair & Company, L.L.C. will act as a co-manager for the proposed offering.

You May Also Be Interested In

• Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
• Serve Robotics (SERV) Opens At $4.75, IIPO At $4 (Earlier)
• Progress Software Corporation (PRGS) Issues Statement on a Possible Offer for MariaDB